Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Leukemia 2Carcinoma, Renal Cell 2Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Kidney Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclosporine 5Cyclophosphamide 5Busulfan 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3thymoglobulin 2Methotrexate 2Antilymphocyte Serum 2venetoclax 1trihexyltetradecylphosphonium chloride 1treosulfan 1tocilizumab 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sirolimus 1Semustine 1Rituximab 1Radiotherapy 1Polymerase Chain Reaction 1Physical Therapy Modalities 1Peripheral Blood Stem Cell Transplantation 1Maraviroc 1Interferon alpha-2 1Immunoenzyme Techniques 1Drug Therapy 1Decitabine 1Cytarabine 1Cyclosporins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Graft vs Host Disease × Interferon alpha-2 × Clear all
NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡